Innovating Works

LEUKANET EV

Desconocido
SafePolyMed: Improve Safety in Polymedication by Managing Drug-Drug-Gene Interactions LEUKANET EV participó en un HORIZON EUROPE: HORIZON-HLTH-2021-CARE-05 Polypharmacy, multimorbidity and genetic heterogeneity can affect drug efficacy, raise the risk for adverse drug reactions (ADRs) and increa...
2022-05-23 - 2025-11-30 | Financiado
HARMONY PLUS: HEALTHCARE ALLIANCE FOR RESOURCEFUL MEDICINES OFFENSIVE AGAINST NEOPLASMS IN HEMATOLOGY PLUS LEUKANET EV participó en un H2020: H2020-JTI-IMI2-2019-19-single-stage Haematological malignancies (HM), also known as blood cancers, are a heterogeneous and complex group of multicausal diseases that can’t be e...
2020-05-26 - 2024-03-31 | Financiado
HARMONY: Healthcare Alliance for Resourceful Medicines Offensive against Neoplasms in HematologY Sofia ref.... LEUKANET EV participó en un H2020: H2020-JTI-IMI2-2015-06-two-stage Despite significant recent progress in the field of hematological malignancies (HMs), with increasing survival rates and improvement in qual...
2016-12-22 - 2023-06-30 | Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.